Literature DB >> 28500412

[Hereditary breast and ovarian cancer].

S F Lax1.   

Abstract

Hereditary breast and ovarian carcinomas are frequently caused by germline mutations of the BRCA1 and BRCA2 genes (BRCA1/2 syndromes) and are often less associated with other hereditary syndromes such as Li-Fraumeni and Peutz-Jeghers. The BRCA1/2 proteins have a special role in DNA repair. Therefore, loss of function due to mutation causes an accumulation of mutations in other genes and subsequent tumorigenesis at an early age. BRCA1/2 mutations are irregularly distributed over the length of the genes without hot spots, although special mutations are known. Breast and ovarian cancer occur far more frequently in women with BRCA1/2 germline mutations compared with the general population. Breast cancer occurs increasingly from the age of 30, ovarian cancer in BRCA1 syndrome from the age of 40 and BRCA2 from the age of 50. Suspicion of a BRCA syndrome should be prompted in the case of clustering of breast cancer in 1st degree relatives, in particular at a young age, if breast and ovarian cancer have occurred, and if cases of male breast cancer are known. Breast carcinomas with medullary differentiation seem to predominate in BRCA syndromes, but other carcinoma types may also occur. BRCA germline mutations seem to occur frequently in triple-negative breast carcinomas, whereas an association with ductal carcinoma in situ (DCIS) is rare. Ovarian carcinomas in BRCA syndromes are usually high-grade serous, mucinous carcinomas and borderline tumors are unusual. Pathology plays a special role within the multidisciplinary team in the recognition of patients with hereditary cancer syndromes.

Entities:  

Keywords:  BRCA germline mutation; Hereditary breast cancer; Hereditary ovarian cancer; Li-Fraumeni syndrome; Peutz-Jeghers syndrome

Mesh:

Year:  2017        PMID: 28500412     DOI: 10.1007/s00292-017-0298-5

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  24 in total

1.  Characterization of BRCA1 and BRCA2 variants found in a Norwegian breast or ovarian cancer cohort.

Authors:  Elisabeth Jarhelle; Hilde Monica Frostad Riise Stensland; Lovise Mæhle; Marijke Van Ghelue
Journal:  Fam Cancer       Date:  2017-01       Impact factor: 2.375

2.  Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer.

Authors:  J M Piek; P J van Diest; R P Zweemer; J W Jansen; R J Poort-Keesom; F H Menko; J J Gille; A P Jongsma; G Pals; P Kenemans; R H Verheijen
Journal:  J Pathol       Date:  2001-11       Impact factor: 7.996

3.  Detection of false positive mutations in BRCA gene by next generation sequencing.

Authors:  Moushumi Suryavanshi; Dushyant Kumar; Manoj Kumar Panigrahi; Meenakshi Chowdhary; Anurag Mehta
Journal:  Fam Cancer       Date:  2017-07       Impact factor: 2.375

Review 4.  BRCA1 and BRCA2: different roles in a common pathway of genome protection.

Authors:  Rohini Roy; Jarin Chun; Simon N Powell
Journal:  Nat Rev Cancer       Date:  2011-12-23       Impact factor: 60.716

5.  Incidental carcinomas in prophylactic specimens in BRCA1 and BRCA2 germ-line mutation carriers, with emphasis on fallopian tube lesions: report of 6 cases and review of the literature.

Authors:  Maria L Carcangiu; Bernard Peissel; Barbara Pasini; Gianbattista Spatti; Paolo Radice; Siranoush Manoukian
Journal:  Am J Surg Pathol       Date:  2006-10       Impact factor: 6.394

6.  Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.

Authors:  Timothy R Rebbeck; Henry T Lynch; Susan L Neuhausen; Steven A Narod; Laura Van't Veer; Judy E Garber; Gareth Evans; Claudine Isaacs; Mary B Daly; Ellen Matloff; Olufunmilayo I Olopade; Barbara L Weber
Journal:  N Engl J Med       Date:  2002-05-20       Impact factor: 91.245

7.  Histopathology, FIGO stage, and BRCA mutation status of ovarian cancers from the Gilda Radner Familial Ovarian Cancer Registry.

Authors:  Bruce A Werness; Susan J Ramus; Richard A DiCioccio; Alice S Whittemore; Kim Garlinghouse-Jones; Ingrid Oakley-Girvan; Yoshiaki Tsukada; Patricia Harrington; Simon A Gayther; Bruce A J Ponder; M Steven Piver
Journal:  Int J Gynecol Pathol       Date:  2004-01       Impact factor: 2.762

Review 8.  Ovarian cancer in Lynch syndrome; a systematic review.

Authors:  J M Helder-Woolderink; E A Blok; H F A Vasen; H Hollema; M J Mourits; G H De Bock
Journal:  Eur J Cancer       Date:  2016-01-13       Impact factor: 9.162

9.  Significant frequency of MSH2/MSH6 abnormality in ovarian endometrioid carcinoma supports histotype-specific Lynch syndrome screening in ovarian carcinomas.

Authors:  Peter F Rambau; Máire A Duggan; Prafull Ghatage; Khadija Warfa; Helen Steed; Renee Perrier; Linda E Kelemen; Martin Köbel
Journal:  Histopathology       Date:  2016-02-26       Impact factor: 5.087

10.  The performance of BRCA1 immunohistochemistry for detecting germline, somatic, and epigenetic BRCA1 loss in high-grade serous ovarian cancer.

Authors:  J L Meisel; D M Hyman; K Garg; Q Zhou; F Dao; M Bisogna; J Gao; N D Schultz; R N Grisham; M Phillips; A Iasonos; N D Kauff; D A Levine; R A Soslow; D R Spriggs
Journal:  Ann Oncol       Date:  2014-10-03       Impact factor: 32.976

View more
  2 in total

Review 1.  Hematological Malignancies in Adults With a Family Predisposition.

Authors:  Tilmann Bochtler; Georg-Martin Haag; Sarah Schott; Matthias Kloor; Alwin Krämer; Carsten Müller-Tidow
Journal:  Dtsch Arztebl Int       Date:  2018-12-14       Impact factor: 5.594

2.  BRCA2 3'-UTR Polymorphism rs15869 Alters Susceptibility to Papillary Thyroid Carcinoma via Binding hsa-mir-1178-3p.

Authors:  Nan Guo; Peng Qu; Hao Li; Liuli Liu; Hao Jin; Renqi Liu; Zhen Zhang; Xuan Zhang; Yingchun Li; Xiaobo Lu; Yuejiao Zhao
Journal:  Pharmgenomics Pers Med       Date:  2021-05-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.